Authors

Thomas Herzog, MD, UC College of Medicine

Thomas Herzog, MD, University of Cincinnati

Latest:

Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic Cancers

Thomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.

Thomas Herzog, MD, University of Cincinnati Cancer Institute

Thomas Hope, MD

Latest:

Dr. Hope on the Impact of Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate Cancer

Thomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Thomas Hutson, DO, PharmD, Baylor Charles A. Sammons Cancer Center

Thomas Hutson, DO, PharmD, FACP, Baylor University Medical Center

Thomas Hutson, DO, PharmD, Texas Oncology–Baylor

Thomas J. Herzog, M.D., Professor of Obstetrics and Gynecology, Deputy Director, University of Cincinnati Cancer Institute

Latest:

Rethinking I-O in PROC: A Potential Answer in Two vs. One

Thomas J. Kipps, MD, PhD

Latest:

The Advent of the BTK inhibitor

Thomas J. Kipps, MD, PhD, UC San Diego Moores Cancer Center

Thomas J. Kipps, MD, UCSD

Thomas J. Lynch, Jr., MD

Latest:

Dr. Lynch on Targeting EGFR Mutation Subtypes in Lung Cancer

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Thomas J. Lynch, MD

Latest:

Precision Medicine: A Promising Future for Treating Cancer

Thomas J. Lynch, MD, director, Yale Cancer Center, Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven, writes about precision medicine in oncology.

Thomas J. Polascik, MD

Latest:

Dr. Polascik on Harmonizing Genetic Testing Guidelines in Prostate Cancer

Thomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.

Thomas J. Semrad, MD

Latest:

Dr. Semrad on SPIDER Program to Understand Resistance to Therapies

Thomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.

Thomas Karasic, MD

Latest:

Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular Carcinoma

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.

Thomas Kipps, MD, PhD

Thomas LeBlanc, MD

Latest:

Dr. Thomas LeBlanc on Patient Shared Decision-Making in Hematologic Malignancies

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

Thomas Lynch, Jr, MD

Latest:

Dr. Lynch on the Immuno-Oncology Network at Bristol-Myers Squibb

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the Immuno-Oncology (IO) Network at Bristol-Myers Squibb.

Thomas M. Churilla, MD

Latest:

Dr. Churilla on Impact of Health Insurance Status on Patients With HNSCC

Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.